The GeoVax Labs (Nasdaq: GOVX) story is no longer just about viruses; it is now also about a stage, a microphone, and a very focused webinar based room of investors at Tribe Public’s CEO Presentation and Q&A Event, which took place earlier…
GeoVax’s (GOVX) latest update on its GEO-MVA program reads less like a small-cap press release and more like a biotech coming-of-age story, with Phase 3 now on the horizon and global health agencies finally circling the dance floor. For investors, the mpox/smallpox…
GeoVax Labs (NASDAQ: GOVX) is stepping into 2026 talking like an inflection‑year story—and, unusually for biotech, it has the clinical, regulatory and manufacturing pieces to at least justify the wardrobe change. While capital remains tight, the company is pairing late‑stage Mpox vaccine…